Table 4.
Liver outpatient clinical status
| Clinical Characteristic | Control patients | COVID patients |
P-valuea OR [95% CI] |
|---|---|---|---|
| Care delays (days) | |||
| Lab work3 | 46 ± 47 | 67 ± 69 | 0.01 |
| Imaging3 | 87 ± 76 | 107 ± 96 | 0.18 |
| Cirrhosis (n) | 42 | 53 | |
| Decompensated cirrhosis | 22 | 26 | 0.64 OR 1.21 [0.63, 2.33] |
| Ascites | 18 | 26 | 0.26 OR 1.50 [0.76, 3.02] |
| Hepatic encephalopathy | 7 | 7 | |
| Variceal bleed | 6 | 5 | 0.77 OR 0.71 [0.17, 2.64] |
| Hepatorenal syndrome | 0 | 0 | |
| Hospitalizations for cirrhosis | 5 | 12 | 0.13 OR 2.48 [0.80, 9.18] |
| Labwork (value, mean ± SD) | |||
| ALT (IU/L) | 44 ± 54 | 58 ± 91 | 0.13 |
| Bilirubin (µmol/L) | 15 ± 15 | 23 ± 41 | 0.13 |
| HBV DNA level (log[10] IU/mL) | 2.2 ± 1.2 | 2.8 ± 2.0 | 0.06 |
| MELD score (cirrhosis patients only) | 14 ± 5.6 | 15 ± 7.4 | 0.69b |
| Imaging | |||
| New liver lesion foundc | 6 | 10 | 0.31 |
Wilcoxon rank sum test for non-parametric data, Fisher’s exact test for categorical data.
As calculated by number of days between appointment date and lab work/imaging date.